215results about "Protease inhibitors" patented technology

The invention relates to the technical field of coating surface preparation, in particular to an anticoagulant coating based on novel tick-derived anticoagulant protein Qinghaenin and a preparation method of the anticoagulant coating. The functional layer of the anticoagulant coating comprises the following components: anticoagulant protein Qinghaenin or a functional peptide fragment Qinghaenin 167-192 of the anticoagulant protein Qinghaenin, wherein the amino acid sequence of the functional peptide fragment is as shown in SEQ ID NO. 2. The preparation method of the anticoagulant coating comprises the following steps: by using a polydopamine coating as a substrate layer, covalently grafting through an amido bond, immobilizing anticoagulant protein Qinghaenin capable of inhibiting FXII factor activation or a functional peptide fragment Qinghaenin 167-192 thereof on the surface of a medical polymer material, and successfully constructing a novel anticoagulant coating. Compared with an unmodified medical polymer material, the modified coating can significantly enhance the hydrophilic performance of the material and inhibit platelet adhesion and activation, finally effectively prolongs the in-vitro blood coagulation time, and shows excellent anticoagulation performance.

The disclosure provides compositions and methods for the detection of renal disease and periodontal disease in mammals.

The invention provides a chemical synthesis method of a TIMP2 protein N-terminal structural domain. An amino acid sequence of an N-terminal structural domain of TIMP2 protein is divided into four segments, the four segments are synthesized by a solid-phase polypeptide synthesis method, full-length linear polypeptide is obtained through natural chemical connection, sulfur removal and sulfydryl removal and acetamino methyl removal, finally impurities in a system are removed, the full-length linear polypeptide is dropwise added into a refolding reaction system, oxidation and refolding reactions are carried out, and the TIMP2 protein is obtained. A target product is obtained. The N-TIMP2 of the N-terminal structural domain of the TIMP2 retains the inhibitory activity of the TIMP2 on the MMP14, the N-TIMP2 obtained through chemical total synthesis can introduce non-natural amino acid to any site in the sequence or perform specific modification or mutation in the synthesis process, an effective tool is provided for researching the specific action mechanism of the N-TIMP2 and the MMP14, and a foundation is further laid for research and development of the MMP14 inhibitor.

Urinastatin glycoforms, urinastatin fusion polypeptides, and related compositions, mixtures, and methods of use, including methods of recombinantly producing and treating diseases, are provided. Embodiments of the present disclosure include an isolated mature urinastatin polypeptide comprising: (i) an O-linked glycosylation site modified with residues Glu-Gly-Ser-Gly (SEQ ID NO: 10) to reduce glycosylation at the O-linked glycosylation site; (ii) an N-linked glycan at residue N45; and (iii) an O-linked glycan at residue T17, a residue defined by SEQ ID NO: 2 or 4, wherein the urinastatin polypeptide has at least one urinastatin activity.

The invention relates to a method for preserving or re-conditioning a transplant by administering recombinant alpha1-antitrypsin (AAT) protein or fragment thereof, expressed in a genetically modified yeast, to said transplant during ex vivo normothermic perfusion prior to transplantation in a subject. Another aspect of the invention relates to a method for preventing and / or reducing ischemic-reperfusion injury (IRI) of a transplant by administering recombinant alpha1-antitrypsin (AAT) protein or a fragment thereof, expressed in a genetically modified yeast, during ex vivo normothermic perfusion of the transplant prior to transplantation in a subject. A further aspect of the invention relates to a preserved transplant, obtainable by the methods of the invention. A further aspect of the invention relates to a perfusate or kit for preserving a transplant, wherein said perfusate comprises AAT or a fragment thereof expressed in a genetically modified yeast.

The present invention provides a novel antigen for soy allergy, a method and kit for diagnosing soy allergy, a pharmaceutical composition containing the antigen, soybeans or soybean products from which the antigen has been removed, and a tester for determining the presence or absence of soybean antigen in a target object. [Solution] The diagnostic kit of the present invention comprises at least one of the proteins identified as (1) to (8), or at least one of the proteins identified as (1α) to (55α).

The specification relates to a method of manufacturing a diabetic foot patient-specific skin regeneration sheet, and a diabetic foot patient-specific skin regeneration sheet.

The present application relates to the field of biomedical detection, specifically to a SPINK1 specific ELISA detection kit for aging detection, the kit contains polyclonal antibodies specific to SPINK1 protein and a color developing reaction system for assisting detection; the kit is also configured with E. coli derived recombinant SPINK1 protein with a purity of more than 99% as a standard for concentration calibration; the specific reagent list supplied in the kit includes horseradish peroxidase labeled antibody, blocking solution, washing buffer, the color developing reaction system is composed of 3,3',5,5'-tetramethylbenzidine solution, and the termination solution for interrupting the color developing chemical reaction is independently packaged. Through prokaryotic expression technology and targeted optimization of core induction conditions, combined with protein affinity chromatography purification process based on imidazole elution mechanism, the present application successfully realizes high-efficiency soluble expression of SPINK1 protein in E. coli vector and obtains recombinant protein with a purity of more than 99%.

Provided is a technology for substituting egg white in a food product. Serpins derived from plants or fungi are utilized to substitute egg white in a food product.

The present disclosure provides a method of making a site-specific antibody to a target of interest.

Compositions and methods for expressing alpha 1 antitrypsin (AAT) in a host cell are provided. Also provided are compositions and methods for treating subjects having alpha 1 antitrypsin deficiency (AATD).

Of the present technology are SERPIN peptide derivatives, methods of making the same, and uses of the same for treating various conditions associated with LRP1 mediation.

The present application relates to a fibroblast activation protein ligand and a use thereof, and in particular to a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, and a use thereof in diagnosis or treatment of diseases related to a fibroblast activation protein, such as tumours or cancers.

Therapeutic mRNA molecules are provided that are expressible to provide a target polypeptide or protein.SOLUTION: The RNA molecule can contain one or more 5-methoxyuridines and 5-methylcytidines. Further provided is a DNA template that can be transcribed to provide a target mRNA and that can have altered nucleotides such as reduced deoxyadenosine. The present invention also provides a process for producing a therapeutic mRNA molecule. An RNA molecule can be translated in vitro or in vivo to provide an active polypeptide or protein.SELECTED DRAWING: Figure 1

Aspects of the present disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBD"), such as ulcerative colitis ("UC") and / or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an outer surface of the core. In some cases, the protease inhibitor is a gligliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and / or small intestine of a subject administered the pharmaceutical dosage form. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., bacterial protease) to the large intestine (e.g., colon) and / or the small intestine of a subject.

The present application relates to the technical field of new materials, in particular to a porous ulinastatin adsorbent with a responsive shell and a preparation method thereof.The porous ulinastatin adsorbent with a responsive shell is a full-synthetic polymer matrix, and has a solid structure.A high-crosslinking-degree polyvinyl alcohol / styrene / divinylbenzene core and a MOF nanoparticle-enhanced framework endow the porous ulinastatin adsorbent with a responsive shell with excellent mechanical strength, and the porous ulinastatin adsorbent with a responsive shell can withstand the pressure in an industrial chromatography column and is not prone to breakage.Because both recognition and desorption are physical processes, the replacement frequency and overall cost of the porous ulinastatin adsorbent with a responsive shell in the production process are greatly reduced, and a reliable guarantee is provided for industrial large-scale and continuous production.

The present invention relates to polypeptides comprising gigastasin variants in which one or more residues have been substituted compared to the naturally occurring gigastasin of the giant Amazon leech. It further relates to processes for their production, to their lectin pathway inhibition, to their half-life extension, and to their therapeutic use.

The present invention relates to a cathepsin K inhibitor comprising or consisting of Formula (I) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (I), wherein (X1) is the amino acid K; (X2) is an amino acid selected from R and W, and is preferably R; (X3) is an amino acid selected from R and W, and is preferably R; (X4) is the amino acid L; (X5) is an amino acid selected from Y, V and W, and is preferably V or Y, and is most preferably V; (X6) is an amino acid selected from I, M, L, W and R, and is preferably I, L or W; and is most preferably I; (X7) is an amino acid selected from H, W, A T, R; and is preferably H or R, and is most preferably R; and (Y) is a Michael acceptor. The present invention also relates to a cathepsin L inhibitor comprising or consisting of Formula (II) (X1)(X2)(X3)(X4)(Y)(X5)(X6)(X7) Formula (II), wherein (X1) is the amino acid K; (X2) is the amino acid R; (X3) is an amino acid selected from R, L and M, and is preferably L; (X4) is an amino acid selected from L, W, F and Y, and is preferably W; (X5) is an amino acid selected from V, H and R, and is preferably V; (X6) is an amino acid selected from M, L, I, W and R, and is preferably L; (X7) is an amino acid selected from W, A T, R; and is preferably W; and (Y) is a Michael acceptor.

The present invention provides specific matrix metalloproteinase (MMP) polypeptide inhibitors and uses thereof in treating MMP-related diseases, in particular cancer, such as breast cancer and glioblastoma.

The present invention provides polypeptide conjugates comprising a sequence of matrix metalloproteinases (MMP) inhibitor and a plurality of heparin-binding peptide, biomaterial particles comprising complexes of said conjugates and alginate sulfate and allowing extended release of the MMP inhibitor and use of said biomaterial particles in treating diseases and conditions in which MMP inhibitors are implicated. Specifically, use of such biomaterial particles comprising MMP-9 inhibitor in preventing cardiac remodeling is provided.

The present disclosure is generally related to methods and compositions for producing heterologous globin proteins of interest in recombinant filamentous fungal cells. Certain embodiments are therefore, directed to compositions and methods for the production of globin proteins, recombinant filamentous fungal strains comprising enhanced globin protein productivity phenotypes, polynucleotides (e.g., expression constructs) encoding one or more globin proteins, industrial scale fermentation, globin protein recovery processes and the like.

The present invention discloses a recombinant antithrombin for use in the treatment of bleeding risk in a subject.

The invention relates to a method for extracting human alpha1-antitrypsin from plasma by a full chromatography method. According to the method, specifically, human plasma or a flow-through liquid obtained after Pg, Fg, IgG and Alb are sequentially extracted from the human plasma is used as a raw material, chromatography preparation is conducted through a two-step chromatography method of CM FF cation exchange chromatography and DEAE FF ion exchange chromatography, according to the method, the yield of human alpha1-antitrypsin is larger than 400 g on the basis of 1000 L of plasma, and the relative purity of a product is larger than 99%.

Herein is reported a nucleic acid comprising in operably linked form a nucleic acid encoding a selection marker, a nucleic acid encoding a self-cleaving peptide sequence, and a nucleic acid encoding a proteinaceous protease inhibitor. Further reported are methods for the recombinant production of a heterologous polypeptide using said nucleic acid as well as a cell comprising said nucleic acid according to the invention. Likewise reported is the use of the nucleic acid according to the invention for increasing the amount of the recombinantly produced heterologous polypeptide by reducing protease cleavage.

The present invention provides engineered AAV vectors, and methods of using vectors, comprising capsid proteins that comprise a sequence that binds to the PL16 protein. In some embodiments, it includes a membrane protein expressed in several cell populations and tissues in the body, including brain microvascular endothelial cells in humans. By the present invention, it was discovered that engineered novel AAV vectors comprising a capsid protein having a sequence that allows the vector to bind to P116 may have an increased ability to provide a gene therapy which crosses the blood brain barrier.

Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and / or full-length HMWK.

The present application discloses a method for treating a protein deficiency in the central nervous system of a subject in need thereof, comprising systemically administering to the subject a therapeutically effective dose of a fusion polypeptide comprising the first protein, wherein the fusion polypeptide comprises: (a) the first protein; (b) a second protein that provides extended circulation-lifetime in vivo and (c) blood brain barrier crossing facilitating peptide; wherein the fusion polypeptide crosses the blood brain barrier (BBB).